SeNostic’s growing R&D pipeline is built to streamline the discovery of drugs that target pathological aggregation-based biomarkers of progressive and chronic diseases. Our programs focus on neurodegenerative diseases such as Alzheimer’s, Parkinson’s and ALS as well as the endocrine disorder Type 2 Diabetes. The biomarkers represented in our portfolio include α-synuclein, tau, amyloid-beta, TDP-43 and IAPP. Our patented SeedCycler® technology provides the core platform for screening and in vitro testing of promising drug candidates to facilitate their translation into clinical application for modifi cation and potential treatment of these diseases.
PIPELINE
The SeNostic pipeline encompasses two programs that target areas in dire need of further research: neurodegenerative diseases and type 2 diabetes.
By targeting aggregation-prone biomarkers with substances that prevent, delay, or resolve amyloid formation, we aim to develop effective drug candidates for translation into clinical studies. Our portfolio contains α-synuclein (Parkinsons’s Disease), tau and amyloid-beta (Alzheimer’s Disease), TDP-43 (Amyotrophic Lateral Sclerosis) and IAPP/amylin (Type 2 Diabetes).
SeNostic´s discovery of potent new medicines is achieved through two complementary strategies: developing our own in-house peptide pool of potential inhibitors, and systematically repurposing existing commercial drugs by screening them against aggregation-based biomarkers relevant to neurodegeneration and Type 2 Diabetes.
OUTLOOK
With our dual approach—innovative peptide development and AI-driven drug repurposing, driven by our proprietary technology platform —SeNostic is paving the way for a new generation of disease-modifying therapies. By combining cutting-edge technology with deep biomarker expertise, we are committed to accelerating the transition from discovery to clinical application. Our goal is to contribute to a future where early intervention and effective treatment of aggregation-related diseases become a reality.
